The MAPK/ERK pathway (also known as the Ras-Raf-MEK-ERK pathway) is a chain of proteins in the cell that communicates a signal from a receptor on the surface of the cell to the DNA in the nucleus of the cell.
The signal starts when a signaling molecule binds to the receptor on the cell surface and ends when the DNA in the nucleus expresses a protein and produces some change in the cell, such as cell division. The pathway includes many proteins, including MAPK (mitogen-activated protein kinases, originally called ERK, extracellular signal-regulated kinases), which communicate by adding phosphate groups to a neighboring protein (phosphorylating it), which acts as an "on" or "off" switch.
When one of the proteins in the pathway is mutated, it can become stuck in the "on" or "off" position, which is a necessary step in the development of many cancers. Components of the MAPK/ERK pathway were discovered when they were found in cancer cells. Drugs that reverse the "on" or "off" switch are being investigated as cancer treatments.
Overall, the extracellular mitogen binds to the membrane receptor. This allows Ras (a Small GTPase) to swap its GDP for a GTP. It can now activate MAP3K (e.g., Raf), which activates MAP2K, which activates MAPK. MAPK can now activate a transcription factor, such as Myc. In more detail:
Receptor-linked tyrosine kinases such as the epidermal growth factor receptor (EGFR) are activated by extracellular ligands, such as epidermal growth factor (EGF). Binding of EGF to the EGFR activates the tyrosine kinase activity of the cytoplasmic domain of the receptor. The EGFR becomes phosphorylated on tyrosine residues. Docking proteins such as GRB2 contain an SH2 domain that binds to the phosphotyrosine residues of the activated receptor. GRB2 binds to the guanine nucleotide exchange factor SOS by way of the two SH3 domains of GRB2. When the GRB2-SOS complex docks to phosphorylated EGFR, SOS becomes activated. Activated SOS then promotes the removal of GDP from a member of the Ras subfamily (most notably H-Ras or K-Ras). Ras can then bind GTP and become active.
Activated Ras activates the protein kinase activity of RAF kinase. RAF kinase phosphorylates and activates MEK (MEK1 and MEK2). MEK phosphorylates and activates a mitogen-activated protein kinase (MAPK).
RAF, and ERK (also known as MAPK) are both serine/threonine-selective protein kinases. MEK is a serine/tyrosine/threonine kinase.
In the technical sense, RAF, MEK, and MAPK are all mitogen-activated kinases, as is MNK (see below). MAPK was originally called "extracellular signal-regulated kinases" (ERKs) and "microtubule associated protein kinase" (MAPK). One of the first proteins known to be phosphorylated by ERK was a microtubule-associated protein (MAP). As discussed below, many additional targets for phosphorylation by MAPK were later found, and the protein was renamed "mitogen-activated protein kinase" (MAPK). The series of kinases from RAF to MEK to MAPK is an example of a protein kinase cascade. Such series of kinases provide opportunities for feedback regulation and signal amplification.
Regulation of translation and transcription
Three of the many proteins that are phosphorylated by MAPK are shown in the Figure. One effect of MAPK activation is to alter the translation of mRNA to proteins. MAPK phosphorylates 40S ribosomal protein S6 kinase (RSK). This activates RSK, which, in turn, phosphorylates ribosomal protein S6. Mitogen-activated protein kinases that phosphorylate ribosomal protein S6 were the first to be isolated.
MAPK regulates the activities of several transcription factors. MAPK can phosphorylate C-myc. MAPK phosphorylates and activates MNK, which, in turn, phosphorylates CREB. MAPK also regulates the transcription of the C-Fos gene. By altering the levels and activities of transcription factors, MAPK leads to altered transcription of genes that are important for the cell cycle.
Regulation of cell cycle entry and proliferation
Role of mitogen signaling in cell cycle progression The ERK pathway plays an important role of integrating external signals from the presence of mitogens such as epidermal growth factor (EGF) into signaling events promoting cell growth and proliferation in many mammalian cell types. In a simplified model, the presence of mitogens and growth factors trigger the activation of canonical receptor tyrosine kinases such as EGFR leading to their dimerization and subsequent activation of the small GTPase Ras. This then leads to a series of phosphorylation events downstream in the MAPK cascade (Raf-MEK-ERK) ultimately resulting in the phosphorylation and activation of ERK. The phosphorylation of ERK results in an activation of its kinase activity and leads to phosphorylation of its many downstream targets involved in regulation of cell proliferation. In most cells, some form of sustained ERK activity is required for cells to activate genes that induce cell cycle entry and suppress negative regulators of the cell cycle. Two such important targets include Cyclin D complexes with Cdk4 and Cdk6 (Cdk4/6) which are both phosphorylated by ERK. The transition from G1 to S phase is coordinated by the activity of Cyclin D-Cdk4/6, which increases during late G1 phase as cells prepare to enter S-phase in response to mitogens. Cdk4/6 activation contributes to hyper-phosphorylation and the subsequent destabilization of retinoblastoma protein (Rb). Hypo-phosphorylated Rb, is normally bound to transcription factor E2F in early G1 and inhibits its transcriptional activity, preventing expression of S-phase entry genes including Cyclin E, Cyclin A2 and Emi1. ERK1/2 activation downstream of mitogen induced Ras signaling is necessary and sufficient to remove this cell cycle block and allow cells to progress to S-phase in most mammalian cells.
Downstream feedback control and generation of a bistable G1/S switch
Growth and mitogen signals are transmitted downstream of the ERK pathway are incorporated into multiple positive feedback loops to generate a bistable switch at the level of E2F activation. This occurs due to three main interactions during late G1 phase. The first is a result of mitogen stimulation though the ERK leading to the expression of the transcription factor Myc, which is a direct activator of E2F. The second pathway is a result of ERK activation leading to the accumulation of active complexes of Cyclin D and Cdk4/6 which destabilize Rb via phosphorylation and further serve to activate E2F and promote expression of its targets. Finally, these interactions are all reinforced by an additional positive feedback loop by E2F on itself, as its own expression leads to production of the active complex of Cyclin E and CDK2, which further serves to lock in a cells decision to enter S-phase. As a result, when serum concentration is increased in a gradual manner, most mammalian cells respond in a switch-like manner in entering S-phase. This mitogen stimulated, bistable E2F switch is exhibits hysteresis, as cells are inhibited from returning to G1 even after mitogen withdrawal post E2F activation.
Dynamic signal processing by the ERK pathway
Single cell imaging experiments have shown ERK to be activated in stochastic bursts in the presence of EGF. Furthermore, the pathway has been shown to encode the strength of signaling inputs though frequency modulated pulses of its activity. Using live cell FRET biosensors, cells induced with different concentrations of EGF illicit activity bursts of different frequency, where higher levels of EGF resulted in more frequent bursts of ERK activity. Furthermore, the dynamics of ERK activation in response to mitogens were found to be relevant for unique downstream responses including timing of S-phase entry in MCF10A cells. Various types of growth factors can also lead to unique ERK dynamics in other cell types effecting cell fate, suggesting the temporal dynamics of ERK activation is a general means of encoding unique gene expression programs by cells.
Integration of mitogen and stress signals in proliferation
Recent live cell imaging experiments in MCF10A and MCF7 cells have shown that a combination of mitogen signaling though ERK and stress signals through activation of p53 in mother cells contributes to the likelihood of whether newly formed daughter cells will immediately re-enter the cell cycle or enter quiescence (G0) preceding mitosis. Rather than daughter cells starting with no key signaling proteins after division, mitogen/ERK induced Cyclin D1 mRNA and DNA damage induced p53 protein, both long lived factors in cells, can be stably inherited from mother cells after cell division. The levels of these regulators vary from cell to cell after mitosis and stoichiometry between them strongly influences cell cycle commitment though activation of Cdk2. Chemical perturbations using inhibitors of ERK signaling or inducers p53 signaling in mother cells suggest daughter cells with high levels of p53 protein and low levels of Cyclin D1 transcripts were shown to primarily enter G0 whereas cells with high Cyclin D1 and low levels of p53 are most likely to reenter the cell cycle. These results illustrate a form of encoded molecular memory though the history of mitogen signaling through ERK and stress response though p53.
Uncontrolled growth is a necessary step for the development of all cancers. In many cancers (e.g. melanoma), a defect in the MAP/ERK pathway leads to that uncontrolled growth. Many compounds can inhibit steps in the MAP/ERK pathway, and therefore are potential drugs for treating cancer,  e.g., Hodgkin disease.
Some MEK inhibitors: cobimetinib, CI-1040, PD0325901, Binimetinib (MEK162), selumetinib, Trametinib(GSK1120212) It has been found that acupoint-moxibustion has a role in relieving alcohol-induced gastric mucosal injury in a mouse model, which may be closely associated with its effects in up-regulating activities of the epidermal growth factor/ERK signal transduction pathway.
RAF-ERK pathway is also involved in the pathophysiology of Noonan's Syndrome, a polymalformative disease, where Simvastatin was proposed as a way to improve CNS-cognitive symptoms of the disorder.
Protein microarray analysis can be used to detect subtle changes in protein activity in signaling pathways. The developmental syndromes caused by germline mutations in genes that alter the RAS components of the MAP/ERK signal transduction pathway are called RASopathies.
- Orton RJ, Sturm OE, Vyshemirsky V, Calder M, Gilbert DR, Kolch W (Dec 2005). "Computational modelling of the receptor-tyrosine-kinase-activated MAPK pathway". The Biochemical Journal. 392 (Pt 2): 249–61. doi:10.1042/BJ20050908. PMC 1316260. PMID 16293107.
- Schulze WX, Deng L, Mann M (2005). "Phosphotyrosine interactome of the ErbB-receptor kinase family". Molecular Systems Biology. 1 (1): 2005.0008. doi:10.1038/msb4100012. PMC 1681463. PMID 16729043.
- Zarich N, Oliva JL, Martínez N, et al. (Aug 2006). "Grb2 is a negative modulator of the intrinsic Ras-GEF activity of hSos1". Molecular Biology of the Cell. 17 (8): 3591–7. doi:10.1091/mbc.E05-12-1104. PMC 1525251. PMID 16760435.
- Avruch J, Khokhlatchev A, Kyriakis JM, et al. (2001). "Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade". Recent Progress in Hormone Research. 56 (1): 127–55. doi:10.1210/rp.56.1.127. PMID 11237210. Archived from the original on 2013-04-14.
- Pende M, Um SH, Mieulet V, et al. (Apr 2004). "S6K1,(-/-)/S6K2(-/-) mice exhibit perinatal lethality and rapamycin-sensitive 5'-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway". Molecular and Cellular Biology. 24 (8): 3112–24. doi:10.1128/MCB.24.8.3112-3124.2004. PMC 381608. PMID 15060135.
- Meloche, et al.. “The ERK1/2 Mitogen-Activated Protein Kinase Pathway as a Master Regulator of the G1- to S-Phase Transition.” Oncogene, vol. 26, no. 22, 2007, pp. 3227–3239., doi:10.1038/sj.onc.1210414.
- Chambard, Jean-Claude, et al. “ERK Implication in Cell Cycle Regulation.” Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, vol. 1773, no. 8, 2007, pp. 1299–1310., doi:10.1016/j.bbamcr.2006.11.010.
- 4. Yao, Guang, et al. “A Bistable Rb-E2F Switch Underlies the Restriction Point.” Nature Cell Biology, vol. 10, no. 4, 2008, pp. 476–482., doi:10.1038/ncb1711.
- Yao, Guang, et al. “A Bistable Rb-E2F Switch Underlies the Restriction Point.” Nature Cell Biology, vol. 10, no. 4, 2008, pp. 476–482., doi:10.1038/ncb1711.
- Albeck, John A G., et al. “Frequency-Modulated Pulses of ERK Activity Transmit Quantitative Proliferation Signals.” Molecular Cell, vol. 49, no. 2, 2013, pp. 249–261., doi:10.1016/j.molcel.2012.11.002.
- Ryu, H., et al. “Frequency Modulation of ERK Activation Dynamics Rewires Cell Fate.” Molecular Systems Biology, vol. 11, no. 11, 2015, pp. 838–838., doi:10.15252/msb.20156458.
- 8. Yang, Hee Won, et al. “Competing Memories of Mitogen and p53 Signalling Control Cell-Cycle Entry.” Nature, vol. 549, no. 7672, June 2017, pp. 404–408., doi:10.1038/nature23880.
- Yang, Hee Won, et al. “Competing Memories of Mitogen and p53 Signalling Control Cell-Cycle Entry.” Nature, vol. 549, no. 7672, June 2017, pp. 404–408., doi:10.1038/nature23880.
- Kedziora, Katarzyna M., and Jeremy E. Purvis. “Cell Biology: The Persistence of Memory.”Nature, vol. 549, no. 7672, June 2017, pp. 343–344., doi:10.1038/nature23549.
- Downward J (2003). "Targeting RAS signalling pathways in cancer therapy". Nature Reviews Cancer. 3 (1): 11–22. doi:10.1038/nrc969. PMID 12509763.
- Hilger RA, Scheulen ME, Strumberg D (December 2002). "The Ras-Raf-MEK-ERK pathway in the treatment of cancer" (PDF). Onkologie. 25 (6): 511–8. doi:10.1159/000068621. PMID 12566895. Archived from the original on 2012-10-06.
- Sebolt-Leopold JS (June 2008). "Advances in the development of cancer therapeutics directed against the RAS-mitogen-activated protein kinase pathway". Clin. Cancer Res. 14 (12): 3651–6. doi:10.1158/1078-0432.CCR-08-0333. PMID 18559577. Archived from the original on 2011-09-06.
- Hoshino R, Chatani Y, Yamori T, et al. (January 1999). "Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors". Oncogene. 18 (3): 813–22. doi:10.1038/sj.onc.1202367. PMID 9989833.
- McCubrey JA, Steelman LS, Chappell WH, et al. (August 2007). "Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance". Biochim. Biophys. Acta. 1773 (8): 1263–84. doi:10.1016/j.bbamcr.2006.10.001. PMC 2696318. PMID 17126425.
- Kwong-Kwok Wong (2009). "Recent Developments in Anti-Cancer Agents Targeting the Ras/Raf/ MEK/ERK Pathway" (PDF). Archived from the original (PDF) on 2010-06-16. Cite journal requires
- Zheng B, Fiumara P, Li YV, et al. (August 2003). "MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival". Blood. 102 (3): 1019–27. doi:10.1182/blood-2002-11-3507. PMID 12689928.
- "Archived copy". Archived from the original on 2012-07-08. Retrieved 2010-11-26.CS1 maint: archived copy as title (link)
- Zhang H, Guo H, Zhang YC, Liu M, Ai K, Su YM, Li MH, Li TL (2014). "[Effect of moxibustion intervention on expression of gastric epidermal growth factor receptor and extracellular signal regulated kinase 1/2 expression in rats with gastric ulcer]". Zhen Ci Yan Jiu. 39: 351–7. PMID 25518106.
- Calvert VS, Tang Y, Boveia V, Wulfkuhle J, Schutz-Geschwender A, Oliver DM, Liotta LA, Petricoin EF (2004). "Development of Multiplexed Protein Profiling and Detection Using Near Infrared Detection of Reverse-Phase Protein Microarrays" (PDF). Clinical Proteomics Journal. 1 (1): 81–89. doi:10.1385/CP:1:1:081. Archived from the original (PDF) on 2011-07-13.